90% of data ready for analysis
Planning cycle time
Shaving just 1 month off of every one of clinical trials
AstraZeneca is a global, science-led biopharmaceutical business with a focus in cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity; infection and neuroscience. There is a fine balance between speed, in terms of how you develop and get drugs into a commercial state and trust: If there is no quality in the data, drugs will not get into a commercial state and can affect the life of patients. Innovation is driven by data. AstraZeneca has built a data lake on AWS and Talend is at the heart of that architecture, growing five times the amount since the start of its data journey.
The focus of Talend has been around the Enabling Units, the global product portfolio strategy and the medical functions. AstraZeneca is now expanding and exploiting the usage of Talend across commercial functions and the science unit. The company is rethinking how to create a drug from scratch, utilize ground-breaking tools like genomic sequencing, advance a drug through the rigors of testing, and shorten the time of clinical trials. Shaving just one month off of each clinical trial will save AstraZeneca $1BN a year.